Edgewise Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 13G, Stake over 5%, passiveAug 6 →Insiders1 insider bought $199,448 in 1 open-market buy. 3 insiders sold $9.7M, 9 of 12 sales on a 10b5-1 plan.→HoldersOrbimed 14.4%Paradigm Biocapital 9.5%Ra 7.8%→PeersClosest companies: TNYA, TRDA, SRPT→
From the filings
Figures
- Net income
- −$29.6Mlast 12 months
- Operating cash flow
- −$148.5Mlast 12 months
- Cash and equivalents
- $72.3Mat the last balance sheet
- Shares outstanding
- 107.8M shareson issue